Jim Cramer was struck by the best letter yet from Warren Buffett. But why must we think he cannot be emulated?» Read More
With Thursday's selloff, Cramer highlights plays that could bring in buyers amid a market of volatility.
Investors held their breath for another wild day, in a whipsaw week that has seen some of the biggest gains—and losses—for stocks all year.
The oil price could face further downward pressure as a warmer winter is expected to hit demand further, OPEC warned.
Some of the names on the move ahead of the open.
After a sharp stock selloff Thursday and erasing the previous day's rally, it's time to get defensive, say CNBC's "Fast Money" traders.
The market is experiencing its most volatile period in five months, and there are few safe harbors amid the sell-off.
The "Fast Money" traders share their final trades of the day.
Follow these tips to pick the best actively managed funds in a crowded field.
Jim Cramer takes on activist calls to CEOs strong performing companies, and suggests they realign their attention
With the importance of cybersecurity growing on a daily basis, Cramer discusses Cyberark Software and the possibility of it being a long-term play
Private equity returns continue to outpace stocks over the long term, according to a new report from an industry association.
With stocks ending sharply on Thursday and Wednesday's big rally, Cramer provides clarity to the market and how to tell what is real.
The news shook the confidence of investors and analysts alike, with four key firms downgrading their ratings on the apparel retailer.
Veteran trader Art Cashin flags a key technical level for the S&P 500 index.
Take a look at some of Thursday's after hours buzz: AMZN, SYMC & more.
The reasons for the CEO shake-up are unknown, but overall Gap "just isn't that bad," says CNBC's Jim Cramer.
Thursday's Good, Bad and Ugly includes Leon Cooperman's stock call amid the recent volatility and Carl Icahn's new Apple letter.
There's starting to be lots of push back on initial public offerings. Investors want to make money rather than just spend it.
The Ebola story has played out in the stock market recently largely on the backs of two companies: drugmakers Chimerix and Tekmira.
The end is nigh for the stock market boom, according to Albert Edwards, Societe Generale’s notoriously bearish global strategist.